Clinical Trial Update: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating combined therapy with D-TACE, gemcitabine, cisplatin, and a PD-1 antibody for unresectable intrahepatic cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• D-TACE
• Gemcitabine (Gemcitabine)
• PD1 antibody

Snippet

Sponsor: Hua Li | Conditions: Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN